ziresovir

Ziresovir is a structurally novel, orally bioavailable small molecule antiviral drug developed for the treatment of respiratory syncytial virus (RSV) infection. It acts as a potent and selective inhibitor of the RSV fusion (F) protein, binding to this viral protein to prevent viral entry into human cells and block cell-to-cell fusion (syncytium formation), which are key steps in RSV pathogenesis[1][4][6][8]. Ziresovir has demonstrated significant efficacy in reducing clinical symptoms and viral load in infants and young children hospitalized with RSV infection during phase 2 and phase 3 clinical trials[1][4][5]. The drug has shown a favorable safety profile with no serious drug-related adverse events reported[1][5]. Ziresovir was discovered by Ark Biosciences following high-throughput screening for anti-RSV activity[6].

Brand names

Ziresovir

Other names

AK-0529AK0529AK 0529RO-0529RO0529RO 0529ElsevirExvet